Combination of the c-Met Inhibitor Tivantinib and Zoledronic Acid Prevents Tumor Bone Engraftment and Inhibits Progression of Established Bone Metastases in a Breast Xenograft Model

• Sara Previdi,

  Affiliation Laboratory of Molecular Pharmacology, Department of Oncology, IRCCS - Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy

  ⨯
• Federica Scolari,

  Affiliation Laboratory of Molecular Pharmacology, Department of Oncology, IRCCS - Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy

  ⨯
• Rosaria Chilà,

  Affiliation Laboratory of Molecular Pharmacology, Department of Oncology, IRCCS - Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy

  ⨯
• Francesca Ricci,

  Affiliation Laboratory of Molecular Pharmacology, Department of Oncology, IRCCS - Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy

  ⨯
• Giovanni Abbadessa,

  Affiliation ArQule, Inc., Woburn, Massachusetts, United States of America

  ⨯
• Massimo Broggini

  * E-mail: massimo.broggini@marionegri.it

  Affiliation Laboratory of Molecular Pharmacology, Department of Oncology, IRCCS - Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy

  ⨯